Recurrent miscarriage: evidence to accelerate action.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
01 05 2021
Historique:
received: 15 07 2020
revised: 11 02 2021
accepted: 16 02 2021
pubmed: 30 4 2021
medline: 7 1 2022
entrez: 29 4 2021
Statut: ppublish

Résumé

Women who have had repeated miscarriages often have uncertainties about the cause, the likelihood of recurrence, the investigations they need, and the treatments that might help. Health-care policy makers and providers have uncertainties about the optimal ways to organise and provide care. For this Series paper, we have developed recommendations for practice from literature reviews, appraisal of guidelines, and a UK-wide consensus conference that was held in December, 2019. Caregivers should individualise care according to the clinical needs and preferences of women and their partners. We define a minimum set of investigations and treatments to be offered to couples who have had recurrent miscarriages, and urge health-care policy makers and providers to make them universally available. The essential investigations include measurements of lupus anticoagulant, anticardiolipin antibodies, thyroid function, and a transvaginal pelvic ultrasound scan. The key treatments to consider are first trimester progesterone administration, levothyroxine in women with subclinical hypothyroidism, and the combination of aspirin and heparin in women with antiphospholipid antibodies. Appropriate screening and care for mental health issues and future obstetric risks, particularly preterm birth, fetal growth restriction, and stillbirth, will need to be incorporated into the care pathway for couples with a history of recurrent miscarriage. We suggest health-care services structure care using a graded model in which women are offered online health-care advice and support, care in a nurse or midwifery-led clinic, and care in a medical consultant-led clinic, according to clinical needs.

Identifiants

pubmed: 33915096
pii: S0140-6736(21)00681-4
doi: 10.1016/S0140-6736(21)00681-4
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1675-1682

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Auteurs

Arri Coomarasamy (A)

Tommy's National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK. Electronic address: a.coomarasamy@bham.ac.uk.

Rima K Dhillon-Smith (RK)

Tommy's National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

Argyro Papadopoulou (A)

Tommy's National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

Maya Al-Memar (M)

Tommy's National Centre for Miscarriage Research, Imperial College London, London, UK.

Jane Brewin (J)

Tommy's Charity, Laurence Pountney Hill, London, UK.

Vikki M Abrahams (VM)

Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University, New Haven, CT, USA.

Abha Maheshwari (A)

Aberdeen Centre of Reproductive Medicine, Aberdeen, UK.

Ole B Christiansen (OB)

Centre for Recurrent Pregnancy Loss of Western Denmark, Department of Obstetrics and Gynaecology, Aalborg University Hospital, Aalborg, Denmark.

Mary D Stephenson (MD)

University of Illinois Recurrent Pregnancy Loss Program, Department of Obstetrics and Gynecology, University of Illinois at Chicago, Chicago, IL, USA.

Mariëtte Goddijn (M)

Center for Reproductive Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Olufemi T Oladapo (OT)

UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Sexual and Reproductive Health and Research, WHO, Geneva, Switzerland.

Chandrika N Wijeyaratne (CN)

Department of Reproductive Medicine, University of Colombo, Colombo, Sri Lanka.

Debra Bick (D)

Warwick Clinical Trials Unit, University of Warwick, Warwick, UK.

Hassan Shehata (H)

Epsom General Hospital, Epsom and St Helier University Hospitals NHS Trust, Epsom, UK.

Rachel Small (R)

Birmingham Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Phillip R Bennett (PR)

Tommy's National Centre for Miscarriage Research, Imperial College London, London, UK.

Lesley Regan (L)

Tommy's National Centre for Miscarriage Research, Imperial College London, London, UK.

Raj Rai (R)

Tommy's National Centre for Miscarriage Research, Imperial College London, London, UK.

Tom Bourne (T)

Tommy's National Centre for Miscarriage Research, Imperial College London, London, UK.

Rajinder Kaur (R)

Tommy's National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

Oonagh Pickering (O)

Tommy's National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

Jan J Brosens (JJ)

Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Warwick, UK; Tommy's National Centre for Miscarriage Research, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.

Adam J Devall (AJ)

Tommy's National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

Ioannis D Gallos (ID)

Tommy's National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

Siobhan Quenby (S)

Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Warwick, UK; Tommy's National Centre for Miscarriage Research, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH